Pulmonx (LUNG) Stock Forecast & Price Target

Pulmonx is on track for growth, with steady additions of U.S. treatment centers and expected resumption of sales in China. They also have promising longer-term drivers, such as the potential expansion of their addressable market and targeted patient identification through their pipeline initiatives. Investors should keep an eye on procedural growth, center productivity, and sales execution as key factors for near-term investor sentiment.

Pulmonx is facing challenges with low revenue and soft quarterly performance, which can be attributed to disruptions in U.S. sales and the absence of China sales. While the company has a strong balance sheet, with a newly secured credit facility and cash reserves, they are expected to experience limited growth in the near term. These challenges will require a strong Q4 performance to rebuild investor confidence and demonstrate their ability to stabilize operations and improve execution consistency. However, the company remains a market leader in bronchoscopic lung volume reduction, which could present long-term potential if they are able to address their current challenges.